BeauBrain Healthcare
Innovative diagnostics for early detection of neurodegenerative diseases using advanced imaging and AI technologies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | KRW4.0b | Early VC | |
| Total Funding | 000k | ||
Related Content
BeauBrain.bio operates in the MedTech and HealthTech sectors, focusing on the early diagnosis and prevention of neurodegenerative diseases such as Alzheimer's. The company leverages advanced imaging techniques like MRI and PET scans, combined with artificial intelligence (AI), to detect biomarkers associated with these conditions. BeauBrain.bio serves healthcare providers, research institutions, and pharmaceutical companies, offering them cutting-edge diagnostic tools to improve patient outcomes. The business model revolves around selling diagnostic software and services, as well as partnering with healthcare institutions for clinical trials and research. Revenue is generated through software licensing, service fees, and collaborative research agreements.
Keywords: neurodegenerative, diagnostics, imaging, AI, MRI, PET, biomarkers, Alzheimer's, healthcare, MedTech.